Lowers the risk of cardiovascular death and hospitalization for heart failure. ANDA 213676, held by Laurus Labs. Sacubitril; Valsartan.
As of Nov 21, 2026, ANDA 213676 (Sacubitril and Valsartan), held by Laurus Labs, was first approved by FDA on May 28, 2024, with 0 approved supplements and 0 published complete response letters.
Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and are expected to improve cardiovascular outcomes. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 28, 2024 | Original application | Approved |
| Sacubitril and Valsartan24MG;26MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan49MG;51MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan97MG;103MG · tablet;oral | Sacubitril; Valsartan | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters